uniQure N.V.
-
Ticker
QURE
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 201-500 Employees
- Based in Amsterdam, Netherlands
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. They are leveraging their modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.
REPORT RATINGS
4.8 / 5.0 (146)
uniQure N.V. reports have an aggregate usefulness score of 4.8 based on 146 reviews.
uniQure N.V.
Most Recent Annual Report
MOST RECENT
2023 Annual Report and Form 10K
View 2023 Corporate Responsibility Report
Older/Archived Annual Reports